Medicyte Coordinates EU-funded Collaboration on Biomimetic Bioartificial Liver
Research is receiving 4.2 Mio Euros from the European Union Seventh Framework Programme.
Medicyte and the Universities of Manchester and Pisa launch a European wide unique project with the aim to design a biomimetic bioartificial liver (Re-Liver). The company GABO:mi ensures professional project management.
The aim of Re-Liver is to reconstitute a standardized and reproducible bioartificial liver organoid (BLO) using healthy human liver as an architectural and biomaterial template. According to the EMA criteria, the BLO is a cell-based medicinal product, a highly innovative and complex medicine. In addition to the Advanced Therapy Medicinal Product (ATMP), new diagnostic tools and further products in cell-based applications will be developed and validated by the Re-Liver Consortium, made up of three industrial partners, all SMEs, focusing the commercialisation of market-leading products across Europe and further afield. The results of Re-Liver could be used for minimal invasive implantation to treat metabolic diseases, such as Haemophilia A, minimizing the transition from concept to clinic, and finally as an alternative for solid organ transplantation - giving new hope to over 10,000 people waiting for a liver transplant in the EU.
This research is receiving funding (4.2 Mio Euros) from the European Union Seventh Framework Programme (FP7/ 2007-2013) under grant agreement n° 304961.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
